Table 1.
CSC markers which have been used as therapeutic targets in different tumors.
| Tumor types | CSC target | Reference |
|---|---|---|
| Hematological malignance | ||
| Leukemia | CD90, CD34, CD123, CLL-1, ALDH, CD38 | (11–16) |
| Solid tumor | ||
| Liver cancer | CD44, CD133, CD90, EpCAM, ALDH, CD13, OV-6, α2δ1, ICAM-1 | (17–23) |
| Pancreatic cancer | CD44, CD133, CD73, DCLK1, CXCR4, ABCB1, STAT3, CD47 | (24–30) |
| Gastric cancer | CD44, CD133, CD24, CXCR4, ALDH, EpCAM, LGR5 | (31–37) |
| Breast cancer | CD44, CD133, CD29, CD90, DLL1 | (38–41) |
| Breast cancer | CD44, CD133, LGR5 | (42–44) |
| Urinary cancer | CD44, CD133, CD105 | (45–47) |
DLL1, delta-like canonical Notch ligand; STAT, signal transducer and activator of transcription; CXCR4, C–X–C chemokine receptor type 4; LGR5, leucine-rich repeat containing G protein-coupled receptor 5; ICAM-1, intracellular adhesion molecule 1; DCLK1, doublecortin-like kinase 1; CLL-1, C-type lectin-like molecule-1; OV-6, oval cell marker antibody; ABCB1, ATP-binding cassette subfamily B member 1.